This includes the CDK7 inhibitor THZ1, which leads to potent suppression of the TAL1 enhancer in Jurkat T-ALL cells, raising the possibility that targeting noncoding drivers of oncogenes may offer an exploitable therapeutic window in cases where oncogenes are aberrantly expressed but do not carry an obvious cytogenetic change (Kwiatkowski et al., 2014). The gene discussed is TAL1; the disease is acute lymphoblastic leukemia.